Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future

B. Hellmich, A. F. Águeda, S. Monti, R. Luqmani

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies. Recent Findings: While glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Summary: Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking.

Original languageEnglish
Article number84
JournalCurrent Rheumatology Reports
Issue number12
Publication statusPublished - Dec 1 2020


  • Biologics
  • Giant cell arteritis
  • Glucocorticoids
  • Large vessel vasculitis
  • Takayasu arteritis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future'. Together they form a unique fingerprint.

Cite this